U.S. Neurological Rehabilitation Devices Market: 14.24% CAGR

Market Outlook

By 2032, the U.S. Neurological Rehabilitation Devices Market is projected to reach approximately USD 2.49 billion, expanding at a CAGR of 14.24% during the forecast period 2027–2032. The market was valued at USD 1.12 billion in 2026, with historical analysis covering 2023 to 2025. Values throughout this report are expressed in USD billions.

The market expanded from approximately USD 0.76 billion in 2023 to USD 0.86 billion in 2024 and USD 0.98 billion in 2025, reflecting increasing utilization of robotic therapy platforms, functional electrical stimulation systems, wearable rehabilitation devices, body-weight support systems, brain-computer interfaces, sensor-based therapy equipment, and connected home rehabilitation technologies. The scope of this market is intentionally focused on neurological rehabilitation technologies rather than broad physical therapy equipment, conventional mobility aids, general-purpose wheelchairs, or neurological implants whose primary function is disease treatment rather than functional rehabilitation.

Demand is supported by a substantial and recurring neurological disability pool. More than 795,000 people experience a stroke in the United States each year, including approximately 610,000 first strokes and 185,000 recurrent strokes. Stroke therefore remains the single most commercially important neurological rehabilitation pathway because survivors frequently require gait retraining, upper-extremity therapy, balance training, neuromuscular re-education, speech and cognitive rehabilitation, and prolonged home-based recovery.

The addressable patient population extends significantly beyond stroke. Approximately 1.1 million people in the U.S. are living with Parkinson’s disease, with close to 90,000 new diagnoses annually, while about 302,000 Americans live with spinal cord injury and approximately 18,000 new SCI cases occur annually. CDC data additionally indicate approximately 214,110 TBI-related hospitalizations, illustrating the large acute-to-post-acute rehabilitation funnel supporting neurological device utilization.

The strongest growth is occurring where neurological rehabilitation shifts from therapist-dependent manual treatment toward high-repetition, measurable and technology-assisted recovery. Hospitals and rehabilitation providers increasingly evaluate devices based on whether they can increase therapy intensity, extend treatment beyond scheduled therapist hours, quantify functional improvement, reduce fall risk, permit earlier mobilization, support therapist productivity, and transition patients safely into outpatient or home settings.

Reimbursement is also beginning to influence market structure more materially. Medicare established a USD 91,032 lump-sum purchase fee schedule amount for personal exoskeletons under HCPCS K1007, while upper-extremity robotic orthotic reimbursement has also become more defined through MyoPro HCPCS payment rates. These developments improve the commercial pathway for technologies that historically relied heavily on institutional capital budgets or private-pay purchasing.

Introduction

According to the U.S. Neurological Rehabilitation Devices Market Report, neurological rehabilitation is evolving from a labor-intensive service model into an increasingly technology-enabled continuum covering acute hospitalization, inpatient rehabilitation, outpatient neurotherapy, specialized rehabilitation hospitals, physician-directed home therapy, and digitally supervised recovery.

The U.S. is particularly attractive for advanced neurological rehabilitation devices because it combines a large neurological disease burden with sophisticated rehabilitation hospitals, academic medical centers, specialty neurological programs, substantial Medicare exposure, private insurance coverage, veteran rehabilitation programs, strong clinical research infrastructure, and one of the world’s most active medical robotics and neurotechnology ecosystems.

The care environment is already large enough to support differentiated device platforms. More than 1,100 inpatient rehabilitation facilities report data to CMS, while CMS used approximately 1,175 inpatient rehabilitation facilities when developing its FY2027 payment policy analysis. Neurological conditions are deeply embedded within inpatient rehabilitation economics, and Medicare’s IRF classification methodology requires at least 60% of an eligible facility’s inpatient population to require rehabilitation for designated qualifying conditions.

Unlike conventional rehabilitation equipment markets dominated by exercise hardware, neurological rehabilitation devices increasingly combine mechanics, sensing, software, stimulation and neurophysiological feedback. Modern platforms can detect movement intent, dynamically support limbs, trigger functional electrical stimulation, quantify range of motion, adapt resistance, protect against falls, deliver hundreds of repetitions, track adherence, and generate longitudinal functional datasets.

The demographic environment strengthens this opportunity. The U.S. population aged 65 years and older reached approximately 61.2 million in 2024, representing 18.0% of the national population. Aging materially increases exposure to stroke, Parkinson’s disease, neurological gait impairment and other conditions requiring rehabilitation.

Through 2032, competitive advantage will increasingly depend on whether manufacturers can move beyond selling stand-alone rehabilitation machines. Hospital and health-system buyers are showing greater interest in platforms that combine hardware, patient assessment, treatment protocols, therapy analytics, remote monitoring, clinician dashboards and reimbursement support.

Key Market Drivers: What’s Fueling the U.S. Neurological Rehabilitation Devices Market Boom?

The first and most durable market driver is the large neurological disability burden. Stroke alone generates more than 795,000 events annually in the U.S., and many survivors experience persistent motor, gait, balance or upper-extremity deficits requiring rehabilitation beyond hospital discharge. Stroke-related healthcare costs already exceed USD 50 billion annually, making technologies that improve functional independence and reduce longer-term care requirements economically relevant to providers and payers.

The second driver is the need to increase rehabilitation intensity without increasing therapist hours proportionally. Traditional neurological therapy is constrained by workforce availability, scheduling, fatigue and reimbursement limits. Robotic systems and digitally guided devices allow repetitive, task-specific movement while clinicians supervise more complex aspects of treatment. A 2024 meta-analysis of 34 randomized trials involving 1,166 stroke participants found that lower-limb robotic exoskeleton training improved multiple gait, balance and walking-independence outcomes relative to conventional rehabilitation in selected settings.

The third driver is the expansion of the post-acute and home rehabilitation continuum. Neurological recovery frequently continues for months or years after an acute event, yet therapy utilization usually falls sharply after inpatient rehabilitation. This treatment gap is creating demand for portable robotic systems, connected functional electrical stimulation platforms, home-based upper-extremity devices, wearable orthotics and brain-computer-interface technologies.

The fourth driver is reimbursement maturation for personal rehabilitation technology. Medicare’s establishment of an approximately USD 91,032 payment amount for personal exoskeletons marked an important commercial precedent for advanced wearable mobility technology. Myomo’s Medicare fee schedule rates of approximately USD 33,480.90 and USD 65,871.74 for two MyoPro configurations further demonstrate that high-value neurological assistive robotics can move beyond exclusively private-pay or institution-funded models.

The fifth driver is the rising prevalence of chronic progressive neurological conditions. Parkinson’s disease affects approximately 1.1 million Americans and is expected to reach approximately 1.2 million by 2030. Multiple sclerosis affects roughly 914,000 people in the United States, with mobility, fatigue, balance, coordination and upper-extremity impairment creating recurring rehabilitation needs over the course of disease.

The sixth driver is the shift toward measurable rehabilitation outcomes. Payers and hospital value-analysis committees increasingly expect documentation that a technology improves walking speed, balance, range of motion, Fugl-Meyer scores, functional independence, activities of daily living, fall risk or therapy productivity. Systems capable of producing objective longitudinal performance data are therefore gaining an advantage over conventional devices that provide therapy without measurable digital endpoints.

Innovation in Focus: How Manufacturers Are Raising the Bar?

The most important innovation trend is the convergence of robotics and neuroplasticity-focused rehabilitation. Modern systems no longer simply move an impaired limb. They alter assistance according to patient effort, provide visual or tactile feedback, record repetitions, monitor symmetry and gradually increase patient participation as recovery progresses.

Lower-extremity rehabilitation is becoming more sophisticated through powered exoskeletons, robotic gait trainers and dynamic body-weight support. Devices such as EksoNR and Indego Therapy are intended to support impaired walking, while dynamic systems such as ZeroG allow patients to perform aggressive gait and balance exercises while reducing fall risk. FDA records describe Indego Therapy as a powered exoskeleton intended to restore walking function in impaired individuals.

Upper-extremity rehabilitation is undergoing a similar transition. Robotic systems are increasingly designed around shoulder biomechanics, reaching, elbow control, wrist movement and hand opening. Portable systems are particularly important because upper-limb recovery often requires thousands of repetitions that cannot economically be provided through one-to-one therapist interaction alone.

Brain-computer interfaces represent a more disruptive innovation layer. Neurolutions’ IpsiHand became the first FDA-authorized BCI rehabilitation device for chronic stroke and links non-invasive brain signals with a robotic handpiece. The technology effectively turns cortical movement intent into assisted physical motion, creating an entirely different rehabilitation pathway for patients whose voluntary hand movement remains severely limited.

Functional electrical stimulation is also becoming more integrated. Contemporary FES systems coordinate stimulation with cycling, stepping or task-specific movements rather than operating as isolated muscle stimulators. Restorative Therapies’ RT300, for example, combines FES with repetitive exercise and software-based performance tracking, while Bioness platforms target gait and upper-extremity impairment associated with upper motor neuron injury.

A further innovation frontier is the decentralization of neurological rehabilitation. Portable robotic hand and foot systems, connected wearable devices, remote coaching and home-based neurotechnology are extending rehabilitation into the patient’s daily environment. This changes procurement economics from one-time hospital capital purchases toward device rental, DME reimbursement, subscriptions, home deployment and recurring software-supported care models.

Segmentation Insights

The U.S. Neurological Rehabilitation Devices Market is segmented by product type, therapy area, functional application, end user, deployment model and geography.

By Product Type

Neurorobotics and Robotic Therapy Systems

Neurorobotics represents one of the largest and highest-value product categories because systems frequently combine mechanical assistance, sensing, software and clinical analytics. The segment includes lower-extremity exoskeletons, treadmill robotics, upper-extremity robotic systems, robotic gait trainers and multi-joint rehabilitation platforms.

Clinical evidence continues to improve. A 2024 review evaluating 34 randomized trials and 1,166 stroke patients found improvements across motor control, walking independence, gait velocity and balance with lower-extremity robotic exoskeleton training in selected patient populations. This evidence base is important because U.S. rehabilitation hospitals increasingly demand measurable outcomes before allocating six-figure capital budgets.

Wearable Rehabilitation and Powered Orthotic Devices

Wearable systems are among the fastest-growing categories because they can bridge institutional and home rehabilitation. Products include powered upper-extremity orthoses, personal exoskeletons, sensor-equipped gait devices and wearable assistive robotics.

Reimbursement has materially strengthened this category. Personal exoskeleton code K1007 received a Medicare lump-sum payment amount of roughly USD 91,032, while MyoPro reimbursement established five-figure to mid-five-figure Medicare payment levels depending on device configuration. These payment pathways improve patient access and create stronger commercial economics for manufacturers.

Functional Electrical Stimulation and Neuromuscular Stimulation Devices

FES and NMES systems are widely relevant to patients with stroke, spinal cord injury, multiple sclerosis, traumatic brain injury and cerebral palsy. Devices stimulate impaired muscles in coordinated patterns to facilitate muscle re-education, gait, cycling, grasping or task-specific movements.

The addressable clinical pool is substantial: approximately 302,000 Americans are living with spinal cord injury, while more than 795,000 strokes occur annually. Integrated FES platforms are particularly attractive when they combine stimulation with measurable exercise, biofeedback and home-use capability.

Brain-Computer Interface and Neurofeedback Systems

BCI is smaller in current revenue but represents one of the most strategically important subsegments. These systems convert EEG or other neurological signals into device actions, enabling rehabilitation even when physical movement is severely impaired.

FDA authorization of IpsiHand created a regulatory precedent for non-invasive BCI-based stroke rehabilitation. Commercial expansion of this category through 2032 is likely to depend on clinical evidence, simplified fitting, payer coverage and whether systems can demonstrate durable improvement in activities of daily living.

Sensor-Based, Virtual and Interactive Rehabilitation Devices

Sensor-based systems use accelerometers, force sensors, motion tracking, gaming and visual feedback to increase therapy engagement and objectively measure patient performance. Neofect’s Smart Glove, for example, tracks movements of the forearm, wrist and digits and combines these measurements with interactive rehabilitation activities.

This category benefits from lower hardware intensity than full robotic systems and is therefore well positioned for outpatient clinics, rehabilitation networks and home recovery.

Dynamic Body-Weight Support and Gait Systems

Dynamic body-weight support systems address gait, balance, fall protection and early mobilization. These systems allow clinicians to challenge patients more aggressively while reducing the consequences of falls.

Technology specifications within this segment can accommodate wide clinical ranges. Aretech’s ZeroG platform, for example, supports patients up to approximately 450 pounds and provides dynamically adjustable body-weight support during gait and balance therapy.

By Therapy Area

Stroke Rehabilitation

Stroke is the dominant therapy area because more than 795,000 events occur annually, and motor impairment can affect gait, balance, upper-extremity function and activities of daily living. Stroke accounted for the largest therapy-area share in published U.S. neurorehabilitation benchmarks, reflecting the breadth of applicable technologies from gait robotics to BCIs.

The subsegment benefits from both acute rehabilitation and a very large chronic survivor pool, making home-based technologies particularly attractive.

Parkinson’s Disease Rehabilitation

Approximately 1.1 million Americans live with Parkinson’s disease, and nearly 90,000 new diagnoses occur annually. Rehabilitation technology is used to address gait freezing, balance impairment, reduced movement amplitude, coordination loss and declining independence.

Because Parkinson’s is progressive, demand differs from stroke. Devices must often support long-term management rather than a finite recovery episode.

Spinal Cord Injury Rehabilitation

Approximately 302,000 Americans live with SCI, with around 18,000 new cases annually. This segment supports exoskeletons, FES cycling, gait robotics, body-weight support systems and upper-extremity rehabilitation.

SCI is particularly important commercially because device intensity can be high and reimbursement precedents for personal exoskeletons are directly relevant.

Traumatic Brain Injury Rehabilitation

CDC reports approximately 214,110 TBI-related hospitalizations in its most recent hospitalization dataset. Rehabilitation requirements vary from severe mobility impairment to balance, cognitive and upper-extremity deficits.

Robotic, sensor-based and digitally guided systems are gaining relevance as providers seek structured ways to manage complex, heterogeneous recovery profiles.

Multiple Sclerosis Rehabilitation

Approximately 914,000 people in the U.S. live with multiple sclerosis. Mobility impairment, fatigue, weakness, spasticity and balance dysfunction create recurring demand for FES, gait training and assistive rehabilitation technology.

Unlike stroke, demand is longitudinal, with device needs frequently changing as disability progresses.

Cerebral Palsy and Other Neurological Conditions

Cerebral palsy is the most common motor disability of childhood, with historical CDC surveillance identifying approximately 1 in 345 U.S. children in monitored populations. Pediatric rehabilitation therefore provides a specialized market for gait systems, FES, robotic training and upper-extremity devices.

Other relevant neurological conditions include acquired brain injury, incomplete paralysis and selected neuromuscular disorders.

By Functional Application

Gait and Balance Rehabilitation

Gait and balance applications represent a major demand center because mobility determines discharge destination, caregiver burden and long-term independence. Technologies include robotic gait trainers, powered exoskeletons, dynamic body-weight support, FES and wearable gait systems.

Clinical studies increasingly support measurable improvements in selected stroke populations, including gait velocity and walking independence.

Upper-Extremity and Hand Rehabilitation

Upper-extremity rehabilitation includes shoulder, elbow, forearm, wrist and hand retraining. High-repetition robotic systems, powered orthoses, sensor gloves and BCIs are increasingly used because manual therapy alone frequently cannot provide the repetition intensity required over months of recovery.

This application is particularly important in chronic stroke, where persistent hand dysfunction remains one of the most difficult disabilities to treat.

Neuromuscular Activation and Motor Re-Education

FES, NMES and biofeedback-enabled systems support muscle re-education, range of motion, spasticity management and prevention of disuse-related deterioration.

Integrated FES platforms can generate thousands of patterned contractions and combine stimulation with active exercise, making this category especially relevant for SCI, MS, stroke and TBI.

Cognitive, Coordination and Dual-Task Rehabilitation

Sensor-driven interactive therapy and virtual rehabilitation systems are increasingly used to combine motor tasks with attention, sequencing and coordination challenges.

This subsegment remains smaller than gait or upper-extremity rehabilitation but is becoming strategically important as providers recognize that successful neurological recovery involves both movement and cognitive control.

Activities of Daily Living and Home Independence

The fastest commercial opportunity may ultimately come from technologies that translate impairment reduction into daily independence. Home systems supporting grasping, walking, dressing, meal preparation and self-directed exercise directly address patient-centered outcomes.

Portable rehabilitation robotics are particularly relevant because therapy can continue beyond limited outpatient sessions.

By End User

Inpatient Rehabilitation Facilities

IRFs represent the highest-intensity neurological rehabilitation environment. More than 1,100 facilities report into CMS rehabilitation datasets, creating a substantial installed base for robotic gait systems, FES, upper-extremity robotics and advanced balance technology.

Purchasing decisions are typically driven by therapist productivity, patient throughput, safety, functional outcomes and the ability to differentiate a neurological service line.

Hospitals and Academic Medical Centers

Large hospitals and academic centers are major early adopters because they treat complex stroke, TBI and SCI populations and frequently participate in clinical research.

They are particularly important for high-capital robotic systems, BCIs and emerging neurotechnology that requires specialized clinician training.

Outpatient Neurorehabilitation and Therapy Centers

Outpatient settings increasingly adopt compact robotics, FES, sensor-based therapy and interactive rehabilitation systems.

The central purchasing requirement is productivity: devices must enable high therapy repetition while fitting into shorter reimbursed visits and smaller treatment spaces.

Home Healthcare and Patient-Directed Rehabilitation

Home rehabilitation is expected to register the strongest growth through 2032. Products such as portable hand and foot robots, personal exoskeletons, wearable orthoses and connected FES systems extend therapy beyond traditional clinical encounters.

Medicare reimbursement developments and remote clinical supervision are making this segment progressively more commercially viable.

Veterans, Research Institutes and Specialty Neurological Programs

The U.S. Department of Veterans Affairs, academic laboratories and specialty neurological programs remain important innovation channels.

These organizations often evaluate technologies before broader community adoption and contribute to evidence generation, particularly in SCI, TBI, stroke and advanced mobility rehabilitation.

By Deployment and Care Delivery Model

Fixed Capital Systems

Fixed platforms include large gait trainers, treadmill robotics, body-weight support systems and multi-joint robotic stations. They require substantial capital budgeting but can support high patient volumes across stroke, SCI and TBI programs.

Large rehabilitation hospitals remain the primary buyers.

Mobile and Portable Clinical Systems

Portable robotics allow equipment to move between therapy areas and require less dedicated floor space. Their value proposition centers on flexibility, lower capital intensity and the ability to deliver more therapy without adding fixed rooms.

Personal Wearable Devices

Wearable orthotics and exoskeletons are increasingly purchased for individual patients rather than facilities. The emergence of Medicare reimbursement materially strengthens this deployment category.

Connected and Home-Based Rehabilitation Systems

Home platforms combine hardware with software, patient guidance, adherence monitoring and sometimes telehealth support.

This model addresses one of the largest structural gaps in neurological rehabilitation: the sharp decline in therapy intensity after discharge from institutional care.

Regional Insights: Where the Market is Growing Fastest

The U.S. Neurological Rehabilitation Devices Market is geographically segmented into the South, Northeast, West and Midwest. Regional performance differs according to stroke prevalence, age structure, neurological disease burden, rehabilitation hospital density, academic neurology concentration, payer mix, technology adoption and availability of specialty rehabilitation programs.

The South represents the largest regional market, while the West is projected to record the fastest growth through 2032. The Northeast remains highly valuable for premium clinical adoption and research, while the Midwest has a strong rehabilitation hospital base and important Parkinson’s and stroke demand clusters.

South

The South represented approximately USD 0.43 billion in 2026 and is projected to reach around USD 0.95 billion by 2032, representing an approximate 14.1% regional CAGR.

The region includes Texas, Florida, Georgia, North Carolina, South Carolina, Tennessee, Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, Virginia, Maryland, Delaware, West Virginia and the District of Columbia.

Stroke burden is a defining regional demand driver. CDC research historically identifies Alabama, Arkansas, Georgia, Louisiana, Mississippi, North Carolina, South Carolina and Tennessee as core Stroke Belt states, where stroke mortality and disability have remained elevated relative to many other regions.

Texas is one of the most commercially important neurological rehabilitation device markets in the U.S. because of its large population, extensive rehabilitation infrastructure, major metropolitan medical centers and sizable stroke and neurological patient volumes. Houston, Dallas-Fort Worth, Austin and San Antonio support advanced rehabilitation programs ranging from exoskeleton therapy to spinal cord injury recovery.

Florida combines one of the nation’s largest older adult populations with substantial stroke, Parkinson’s disease and fall-related neurological rehabilitation demand. Parkinson’s epidemiology research specifically identifies Florida as one of the higher-incidence U.S. areas, reinforcing demand for gait, balance and movement rehabilitation.

North Carolina and Georgia have large academic medical networks and rehabilitation ecosystems capable of adopting robotic gait, upper-extremity and connected home rehabilitation technologies. North Carolina also sits within the traditional Stroke Belt, supporting sustained stroke rehabilitation volumes.

Tennessee, Alabama, Mississippi, Louisiana and Arkansas have elevated neurological disability needs but more uneven access to advanced rehabilitation facilities outside major metropolitan areas. This makes portable, remotely supported and home-based rehabilitation especially relevant.

Virginia and Maryland benefit from large integrated health systems, federal healthcare infrastructure, advanced rehabilitation providers and proximity to research organizations.

For manufacturers, the South offers a dual commercial opportunity: premium capital platforms in large urban rehabilitation hospitals and scalable home or portable technologies for broader geographic coverage.

Northeast

The Northeast represented approximately USD 0.28 billion in 2026 and is expected to reach around USD 0.58 billion by 2032, reflecting an approximate CAGR of 12.9%.

The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Rhode Island, Vermont, New Hampshire and Maine.

The Northeast has a disproportionate concentration of nationally recognized academic medical centers, neurological institutes, rehabilitation hospitals and research programs. This makes the region strategically more important than its population alone would suggest.

New York is the largest commercial market in the region due to its population, health-system density and large post-acute care infrastructure. New York City and surrounding metropolitan areas support high-volume stroke, brain injury and neurological rehabilitation programs and are attractive launch markets for premium systems.

Massachusetts is particularly important for medical robotics, neuroscience and rehabilitation innovation. Boston’s academic environment supports early clinical evaluation, evidence development and specialist adoption.

Pennsylvania combines substantial stroke and neurological disease volumes with large integrated health systems. Central Pennsylvania has also been identified as a higher-incidence Parkinson’s disease geography, increasing demand for movement and gait rehabilitation.

New Jersey and Connecticut benefit from high insurance coverage, dense rehabilitation networks and proximity to New York academic centers.

The northern Northeast also has strong relevance for multiple sclerosis. U.S. MS prevalence historically rises at more northern latitudes, making Maine and other northern states meaningful long-term markets for mobility, balance and FES technologies.

The Northeast is likely to remain one of the country’s strongest regions for high-complexity technologies such as BCI rehabilitation, advanced upper-extremity robotics and data-rich neurorehabilitation platforms, although growth is moderated by market maturity and slower population expansion.

West

The West represented approximately USD 0.25 billion in 2026 and is projected to increase to around USD 0.62 billion by 2032, producing an approximate 16.3% CAGR, the fastest among the four U.S. regions.

The region includes California, Washington, Oregon, Arizona, Nevada, Colorado, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska and Hawaii.

California is the most important state market in the region and one of the most influential nationally. It combines a large patient population with academic medical centers, rehabilitation hospitals, medtech engineering, venture-backed neurotechnology companies and digitally oriented health systems.

California is particularly important for brain-computer interfaces, wearable rehabilitation devices, robotics, software-enabled therapy and connected home recovery. Southern California has additionally been identified as a higher-incidence Parkinson’s disease geography.

Arizona has a rapidly growing older population and several major neurological rehabilitation providers. The state is becoming an important commercial market for stroke, Parkinson’s and balance-related technologies.

Washington and Oregon offer sophisticated integrated health systems and relatively strong digital-health adoption. Connected rehabilitation and remote therapy models therefore have attractive commercial potential.

Colorado and Utah have expanding rehabilitation networks and strong technology ecosystems. Their combination of population growth and integrated delivery networks makes them attractive for portable and software-enabled rehabilitation devices.

Nevada, Idaho and New Mexico provide smaller but growing markets where regional access challenges strengthen the economic case for home-based therapy and devices that reduce travel frequency.

The West’s leadership in digital health and medical technology entrepreneurship should support faster adoption of sensor-based rehabilitation, remote monitoring, AI-supported therapy progression and patient-controlled home technology.

Midwest

The Midwest represented approximately USD 0.16 billion in 2026 and is forecast to reach around USD 0.34 billion by 2032, reflecting an approximate 13.4% CAGR.

The region includes Illinois, Ohio, Michigan, Minnesota, Wisconsin, Indiana, Missouri, Iowa, Kansas, Nebraska, North Dakota and South Dakota.

The Midwest has a strong base of major academic hospitals, rehabilitation institutions and regional referral networks. It also contains areas associated with elevated Parkinson’s incidence within the broader U.S. “Rust Belt.”

Illinois is the region’s most important neurological rehabilitation market, led by Chicago’s highly developed academic and rehabilitation ecosystem. Research involving robotic exoskeletons and advanced mobility technology has been conducted through leading Chicago rehabilitation institutions, strengthening the state’s relevance for early adoption.

Ohio and Michigan have substantial stroke and chronic neurological disease populations and mature hospital networks, creating stable demand for gait rehabilitation, FES and upper-extremity systems.

Minnesota benefits from a large medical device ecosystem and highly sophisticated provider organizations, making it strategically important for product evaluation and technology procurement.

Wisconsin, Indiana and Missouri provide stable demand through regional health systems and rehabilitation networks.

Smaller rural markets such as Iowa, Kansas, Nebraska and the Dakotas face longer travel distances to advanced neurorehabilitation programs. Home rehabilitation, tele-supervised therapy and portable devices therefore offer meaningful opportunity.

The Midwest is less likely than the West to lead early consumer-style adoption of connected rehabilitation, but its strong rehabilitation institutions, large chronic disease populations and disciplined health-system purchasing make it an important market for clinically validated and economically defensible technologies.

Key Market Players

The U.S. neurological rehabilitation devices competitive landscape remains fragmented, with specialist robotics, FES, wearable technology and neurotechnology companies competing alongside established rehabilitation platform vendors.

Competition increasingly centers on clinical evidence, therapy intensity, device utilization, reimbursement support, training requirements, home deployment, data capture and integration into existing physical and occupational therapy workflows.

Some of the highly relevant players operating in the U.S. Neurological Rehabilitation Devices industry are:

Ekso Bionics Holdings, Inc.
Lifeward Ltd.
DIH / Hocoma
Tyromotion Inc.
Bioness Medical, Inc.
Bionik Laboratories Corp.
Myomo, Inc.
Neurolutions, Inc.
Harmonic Bionics, Inc.
Restorative Therapies, Inc.
Neofect USA
Motus Nova LLC
Aretech, LLC
Saebo, Inc.
Biometrics Ltd.

Ekso Bionics and Lifeward are particularly important in lower-extremity exoskeleton rehabilitation. DIH/Hocoma and Tyromotion compete across robotic gait and upper-extremity rehabilitation ecosystems. Bioness Medical and Restorative Therapies maintain strong positions in electrical stimulation and neurological rehabilitation, while Myomo has created a differentiated reimbursement-supported pathway in wearable upper-extremity robotics.

Neurolutions represents an emerging BCI-based model, Harmonic Bionics is focused on sophisticated upper-extremity robotics, and Motus Nova and Neofect illustrate the industry’s movement toward portable and home-based neurorehabilitation.

Future market share will be determined less by mechanical sophistication alone and more by the manufacturer’s ability to prove clinical value, support reimbursement, fit therapist workflows, provide patient training, generate measurable outcomes and create economically viable home-deployment pathways.

Recent Developments

One of the most commercially important developments was Medicare’s establishment of a USD 91,032 fee schedule amount for personal exoskeletons under HCPCS K1007 in 2024. The decision materially improved the reimbursement environment for wearable robotic walking technology and demonstrated that CMS could recognize the distinct value of advanced exoskeleton systems.

Upper-extremity wearable robotics also gained reimbursement clarity. CMS established average Medicare payment rates of approximately USD 33,480.90 for MyoPro Motion W and USD 65,871.74 for Motion G, effective April 2024. This development strengthened the commercial pathway for powered orthotic systems used by patients with neurological upper-extremity impairment.

The Bioness competitive structure changed materially when Bioventus completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners at the beginning of 2025. The transferred business included products such as L300 Go, H200 and rehabilitation systems addressing neurological motor impairment. Bioventus reported that the business represented roughly USD 50 million in annual revenue before divestiture, illustrating the commercial scale that specialized neurological rehabilitation portfolios can achieve.

Brain-computer-interface rehabilitation is moving from research into commercial deployment. Neurolutions moved IpsiHand from FDA De Novo authorization into broader commercial launch, creating a differentiated home and clinic rehabilitation approach for chronic stroke survivors.

Upper-extremity robotics also continue to expand. Harmonic Bionics commercially launched its Harmony SHR robotic rehabilitation system following FDA registration and subsequently expanded installations beyond its initial U.S. deployment.

Reimbursement for rehabilitation facilities remains supportive of investment. For FY2027, CMS finalized a 2.3% update to IRF PPS payment rates, reinforcing continued federal funding of the institutional rehabilitation environment in which many advanced neurological systems are initially deployed.

Conclusion

The U.S. Neurological Rehabilitation Devices Market Size & Share is positioned to expand from USD 1.12 billion in 2026 to approximately USD 2.49 billion by 2032, representing a 14.24% CAGR during 2027–2032.

The market’s momentum is grounded in structural rather than temporary demand. More than 795,000 strokes occur annually, approximately 1.1 million Americans live with Parkinson’s disease, roughly 302,000 people live with spinal cord injury, close to one million Americans live with multiple sclerosis, and hundreds of thousands of patients enter the health system each year with significant traumatic brain injury.

The highest-growth technologies will be robotic gait systems, wearable powered rehabilitation devices, brain-computer interfaces, integrated FES platforms, portable upper-extremity robotics and connected home rehabilitation. These technologies address a central economic problem in U.S. rehabilitation: patients require far more repetitive therapy than health systems can economically provide through therapist labor alone.

Stroke will remain the dominant therapy area, but Parkinson’s disease, SCI, TBI and MS provide substantial recurring demand. Inpatient rehabilitation facilities and specialty hospitals will continue to drive high-value capital purchasing, while personal wearable devices and home-based platforms will expand faster as reimbursement and remote-care infrastructure improve.

Regionally, the South will remain the largest revenue pool because of population scale, aging demographics and high stroke burden. The West will deliver the strongest growth due to technology adoption and connected-care models. The Northeast will continue to influence premium clinical adoption and evidence generation, while the Midwest will remain a durable institutional rehabilitation market.

For device manufacturers, the competitive question is no longer simply whether robotics or neurotechnology can improve movement. The commercial challenge is whether those technologies can produce measurable functional outcomes while fitting U.S. reimbursement, clinician workflow and care-delivery economics.

The companies best positioned through 2032 will therefore be those capable of combining clinical evidence, hardware differentiation, therapist productivity, patient engagement, reimbursement support, home deployment and objective outcome measurement into one coherent neurological rehabilitation platform.